The Relationship Between Electrical Energy Delivered by Deep Brain Stimulation and Levodopa-Induced Dyskinesias in Parkinson’s Disease: A Retrospective Preliminary Analysis

Marco Prenassi¹, Mattia Arlotti², Linda Borellini³, Tommaso Bocci⁴, Filippo Cogiamanian³, Marco Locatelli³,⁴,⁵, Paolo Rampini³, Sergio Barbieri³, Alberto Priori⁴ and Sara Marceglia¹,³*

¹ Dipartimento di Ingegneria e Architettura, Università Degli Studi di Trieste, Trieste, Italy, ² Newronika SpA, Milan, Italy, ³ Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca’Granda Ospedale Maggiore Policlinico, Milan, Italy, ⁴ “Aldo Ravelli” Research Center for Neurotechnology and Experimental Brain Therapeutics, University of Milan Medical School, Milan, Italy, ⁵ Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Milan, Italy

Background: Adaptive Deep Brain Stimulation (aDBS) is now considered as a new feasible and effective paradigm to deliver DBS to patients with Parkinson’s disease (PD) in such a way that not only stimulation is personalized and finely tuned to the instantaneous patient’s state, but also motor improvement is obtained with a lower amount of energy transferred to the tissue. Amplitude-controlled aDBS was shown to significantly decrease the amplitude-driven total electrical energy delivered to the tissue (aTEED), an objective measure of the amount of energy transferred by DBS amplitude to the patient’s brain. However, there is no direct evidence of a relationship between aTEED and the occurrence of DBS-related adverse events in humans.

Objective: In this work, we investigated the correlation of aTEED with the occurrence of levodopa-induced dyskinesias pooling all the data available from our previous experiments using aDBS and cDBS.

Methods: We retrospectively analyzed data coming from 19 patients with PD undergoing surgery for STN-DBS electrode positioning and participating to experiments involving cDBS and aDBS delivery. Patients were all studied some days after the surgery (acute setting). The aTEED and dyskinesia assessments (Rush Dyskinesia Rating Scale, RDRS) considered in the Med ON-Stim ON condition.

Results: We confirmed both that aTEED values and RDRS were significantly lower in the aDBS than in cDBS sessions (aTEED mean value, cDBS: 0.0278 ± 0.0011 J, vs. aDBS: 0.0071 ± 0.0003 J, p < 0.0001 Wilcoxon’s rank sum; normalized RDRS mean score, cDBS: 0.66 ± 0.017 vs. aDBS: 0.45 ± 0.01, p = 0.025, Wilcoxon’s rank sum test). In addition, we found a direct significant correlation between aTEED and RDRS (ρ = 0.44, p = 0.0032, Spearman’s correlation).
Conclusions: Our results provide a first piece of evidence that aTEED is correlated to the amount of levodopa-induced dyskinesias in patients with PD undergoing STN-DBS, thus supporting the role of aDBS as feasible and safe alternative to cDBS.

Keywords: total electrica energy delivered, adaptive deep brain stimulation, dyskinesia, local field potential (LFP), safety

INTRODUCTION

Increasing evidence supports the safety, feasibility, and efficacy of new deep brain stimulation (DBS) strategies that implement closed-loop adaptive stimulation for patients with Parkinson's Disease (PD) implanted in the subthalamic nucleus (STN) (1–8). Adaptive DBS (aDBS) differs from conventional DBS (cDBS) because it provides electrical stimulation with parameters that are changed real-time according to the analysis of brain signals, especially local field potentials (LFPs) recorded from the same lead implanted for DBS (9, 10). Conversely, cDBS provides a fixed-parameters stimulation, in which amplitude, frequency, and pulse-width remain unchanged throughout the day, without following the clinical state of the patient. The aDBS concept is based on a simple closed-loop model in which a feedback variable is sensed by the system in order to assess the patient's state, and a control algorithm provides the new stimulation parameters to be delivered to the patient (9). To date, even though several options were explored, including external sensors and electrochemical biomarkers (10, 11), there is general consensus on the use of STN LFP-based biomarkers to represent the clinical state of the patient. Among possible oscillations, the LFP beta band (13–35 Hz) has been targeted in most of the experiments in humans (1, 4, 12). There are however other frequency bands suitable to control specific symptoms, such as the gamma (8, 11), or low-frequencies (13), or a combination of them (14). Among possible stimulation parameters (namely amplitude, frequency, and pulse width), all the present implementations and proof-of-concepts of aDBS are based on amplitude-control, whereas frequency and pulse width are kept constant. In fact, even though different frequencies (15, 16) and shorter pulse widths (17, 18) were studied in PD patients, the complexity behind frequency- and pulse width-modulations is still too high to be successfully implemented in closed-loop algorithms.

The general hypothesis behind amplitude-controlled aDBS is to provide an effective stimulation, while reducing the amount of unnecessary stimulation that is delivered by cDBS (19, 20). Stimulation-related side effects are known in patients treated with DBS and are usually reversed by reprogramming (21–24) or by switching stimulation OFF (23). However, in the long term, some of these reversible effects become non-reversible (23, 24), and tend to worsen. This could be due to disease progression, alterations in postoperative medications, comorbidities, but also to possible long-term effects of stimulation, as hypothesized for worsened axial symptoms (25). In a similar way, in essential tremor, patients are instructed, if possible, to switch off DBS during the night, in order to decrease the “tolerance effect” (i.e., the need to increase stimulation amplitude to maintain tremor control) (26). In addition, DBS has been shown to impair response inhibition (27), possibly leading to stimulation-induced impulsivity (19, 20, 28, 29) that could result from excessive beta suppression produced by continuous stimulation (20).

Amplitude-controlled aDBS was shown to significantly decrease the amount of energy delivered to the tissue, measured through a specific quantitative parameter (the total electrical energy delivered to the tissue, TEED) (30). Since the present aDBS applications keep frequency and pulse width fixed, the TEED calculated in aDBS experiments is an amplitude-driven TEED (aTEED). In aDBS, decreasing the energy delivered to the tissue is not necessarily related to battery saving, because there is a power consumption related to the sensing and control circuits that counterbalances the saving in stimulation output. This depends also on the type of adaptation strategy implemented. For instance, there are types of aDBS specifically designed to decrease the stimulation delivered to the tissue by switching DBS ON and OFF (1), whereas other types of aDBS are designed to linearly follow the beta power, continuously changing stimulation amplitude within a stimulation window, without switching DBS OFF at any time (4, 31).

The present STN-LFP aDBS implementations follow the dynamic of beta oscillation that is correlated with bradykinesia and rigidity, and that is highly influenced by levodopa dynamics. It is therefore intuitive that an automatic adaptation of stimulation amplitude following beta changes can help controlling the summative effects of medication and stimulation, especially on dyskinesia (21, 32).

Since implantable devices delivering aDBS are not yet on the market, the effects of aDBS were mostly studied in the acute setting, immediately after the surgery for DBS electrode implant. In this limited experimental setting and with the limits of the present implementation that is based on a single biomarker (beta-band LFP), the literature shows that aDBS controls motor symptoms at least as well as cDBS, and sometimes even better than cDBS, and, in addition, provides better control of levodopa-induced dyskinesias when DBS is ON (4–6) and speech disturbances (3), which are common DBS-related side effects.

Even though the acute experimental setting is not suitable for driving definite conclusions on the effectiveness and on the optimal approach of aDBS especially in the long term, it is however possible to start assessing the relationship between aTEED and DBS-related adverse events that occur in the short-term, such as levodopa-induced dyskinesia.

Abbreviations: DBS, Deep Brain Stimulation; LFP, Local Field Potentials; PD, Parkinson’s Disease; RDRS, Rush Dyskinesia Rating Scale; TEED, Total Electrical Energy Delivered to the tissue.
In order to provide an initial piece of evidence on the role of aTEED in the occurrence of stimulation related side effects, in this work, we investigated the correlation of aTEED with levodopa-induced dyskinesias retrospectively considering all the data available from our previous experiments using aDBS and cDBS (5, 6).

METHODS

This is a retrospective study involving 19 rigid-akinetic patients with advanced PD who underwent surgery for a subthalamic nucleus DBS electrode implantation in the Neurosurgery Unit at Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico Hospital in Milan. No surgical complication was experienced by these subjects. Subjects were involved in three studies: the first one was reported by Rosa et al. (5), the second one by Arlotti et al. (6), and the third one is currently in press. All studies were approved by the institutional review board of the Policlinico Hospital and conformed with the Declaration of Helsinki. All patients provided written informed consent to the experimental procedures. Of the 19 patients here reported, 6 were included in the first study (5), 8 in the second one (6), and 5 in the third study. The patients were included in this study if all the measures and scales described below were available. All the experimental sessions took place few days after DBS surgery before the leads were connected to the subcutaneous pulse generator.

Experimental Procedure

The experimental procedures were fully detailed in the previous studies (5, 6), and are summarized in Figure 1.

In brief, the patients from the first study were recorded, evaluated, and stimulated in two different sessions of 2 h each; in one session was delivered aDBS and in the other one cDBS in random order (5). Each experimental session lasted at least 2 h, during which the patient was evaluated three times: (1) after a baseline assessment (OFF DBS and OFF medication, stimOFF/medOFF, after a night withdrawal of medication), (2) after the stimulation was turned on and before levodopa administration (stimON/medOFF, at least 30 min after DBS was turned on), and (3) 40 min after the administration of the usual patient’s levodopa dose increased by 50% (stimON/medON condition). Clinical assessments included an evaluation of motor performance, and dyskinesias.

The patients from the second study were recorded and evaluated in two different days (day 5 and 6 from the electrode implantation), in two different sessions of 8 h each. On the first session, the subjects were recorded and evaluated with normal levodopa intake but without stimulation. On the second session they were stimulated with aDBS; recording, levodopa intake and assessment parameters were the same as of the day before. The patients, in both days, were assessed and recorded in ecological settings (during hospitalization) and freely moving (6).

The patients from the third study were assessed following the same protocol as in Arlotti et al. (6) with the exception that on the first session they received cDBS instead of no stimulation. The day after, they received aDBS.

All the clinical details of the patients of the three groups are reported in Table 1.

aDBS and cDBS

In all studies, aDBS and cDBS were both delivered using the AlphaDBS V-ext system (31), an external portable device able to record and simultaneously deliver voltage-controlled DBS. The device has two modes: cDBS, in which the stimulation is delivered with fixed parameters, at the effective stimulation amplitude, and aDBS in which stimulation parameters are changed linearly according to the beta band power, with the stimulation amplitude ranging from 0 to the effective stimulation amplitude. AlphaDBS V-ext was calibrated the day before the first experimental session, according to the procedures described in Rosa et al. (4), in order to provide a personalized aDBS algorithm. aDBS and cDBS were delivered unilaterally, as described in Rosa et al. (5) and Arlotti et al. (6).

In all experiments, cDBS was delivered at 130 Hz, with 60 uV pulse width, and an amplitude that was set by an experienced neurologist according to the observed therapeutic window. cDBS amplitude for all patients receiving cDBS is reported in Table 1 and was kept constant throughout the experimental session (2 or 8 h).

aDBS was delivered according to the adaptive approach described in Arlotti et al. (31). In summary, the adaptive algorithm works only by changing DBS amplitude (pulse width is kept fixed at 60 us and frequency at 130 Hz). DBS amplitude is linearly changed in a pre-defined range (Vmin–Vmax) and it is never turned OFF. The amplitude change follows the beta band amplitude changes as recorded from DBS electrodes. aDBS amplitude ranges (Vmin–Vmax) for all patients are reported in Table 1.

Data Analysis

In this work, we considered dyskinesia assessments conducted using the Rush Dyskinesia Rating Scale (RDRS,cit.) which was available in all studies.

In order to pool data from different studies, we considered one clinical evaluation per patient performed when the medication was effective (peak dose = 45–60 min after levodopa administration) and the stimulation was active (Stim ON - Med ON), considering a timeframe of 20 min (±10 min) centered at the start of the clinical evaluation. The aTEED was calculated in the same time frame.

If the patient received both aDBS and cDBS, we considered one clinical evaluation and related aTEED per each type of stimulation.

The aTEED was calculated using equation 1 following the procedures described in Koss et al. (30). The impedance was measured with a impedance meter (Model EZM 4; Grass, USA) at 30 Hz.

\[
TEED = \sum_{n=0}^{N} \frac{V(nT)^2p_{nf}}{Z_r} \quad [J] \quad (1)
\]
**Statistical Analysis**

Since the purpose of this study is to verify whether the amount of stimulation could be related to levodopa-induced dyskinesias, and since aTEED depends only on the instantaneous DBS amplitude (pulse width and frequency are always fixed at 130 Hz and 60 us) each pair (aTEED, RDRS) was considered as an independent sample, whatever the type of stimulation.

However, to account for the heterogeneity of patients (i.e., the amount of peak dyskinesia differs among patients, as well as the optimal cDBS voltage), we scaled each RDRS and aTEED value by the maximum value of RDRD and aTEED registered in each study protocol. Therefore, the RDRS and aTEED values of patients coming from Rosa et al. (5) were divided by 8 and 30 mJ, respectively, those coming from the (6) study by 18 and 22.8 mJ, and those from the third study in press by 8 and 52.3 mJ. This normalization methodology was chosen in order to preserve the exact scale between the data even though the ranges differ among studies. Then, non-parametric statistics was applied.

As a first step, in order to allow pooling all the data together, we verified that, after normalization, no significant differences were observable between patients belonging to the three studies for both aDBS and cDBS (Kruskal-Wallis test, $p > 0.025$ as per Bonferroni correction).

Second, we verified that, according to the literature, aTEED values were lower in aDBS than in cDBS, and that aDBS was able to better control dyskinesia than cDBS. Since not all patients received both aDBS and cDBS, we considered the two groups as independent, even though some patients received both aDBS and cDBS in two different sessions. To allow the use of independent statistics we verified that there was no correlation between aDBS and cDBS in those patients receiving both treatments (aTEED: $p = 0.2$, RDRS: $p = 0.2$). Then, we compared the measures of aTEED and RDRS in aDBS ($N = 27$, see Figure 1) vs.
| Case | Sex | Age at surgery | Disease duration [years] | Onset side | Preoperative LEED [mg] | Voltage cDBS [V] | Freq. [Hz] | Width [µs] | Voltage Range aDBS [V] | Reference study |
|------|-----|----------------|--------------------------|------------|-----------------------|-----------------|-----------|----------|------------------------|----------------|
| A1   | M   | 54            | 19                       | R          | 479                   | 2               | 130       | 60       | 0–2                    | (5)            |
| A2   | M   | 50            | 15                       | R          | 892                   | 2               | 130       | 60       | 0–2                    |                |
| A3   | M   | 48            | 7                        | L          | 1,019                 | 2               | 130       | 60       | 0–2                    |                |
| A4   | F   | 68            | 16                       | R          | 1,648                 | 2               | 130       | 60       | 0–2                    |                |
| A5   | M   | 59            | 9                        | L          | 1,200                 | 2               | 130       | 60       | 0–2                    |                |
| A6   | M   | 51            | 8                        | L          | 975                   | 2               | 130       | 60       | 0–2                    |                |
| B1   | M   | 59            | 10                       | R          | 208                   | 3.5             | 130       | 60       | 0.1–3.5                |                |
| B2   | M   | 62            | 9                        | R          | 686                   | 4               | 130       | 60       | 0.1–4                  |                |
| B3   | M   | 67            | 12                       | R          | 1,494                 | 3               | 130       | 60       | 0.1–3                  |                |
| B4   | M   | 50            | 8                        | R          | 1,055                 | 3               | 130       | 60       | 0.1–3                  |                |
| B5   | M   | 47            | 11                       | R          | 1,080                 | 3.5             | 130       | 60       | 0.1–2.5                |                |
| B6   | M   | 70            | 12                       | L          | 872                   | 2.5             | 130       | 60       | 0.1–3                  |                |
| B7   | M   | 54            | 13                       | L          | 785                   | 3               | 130       | 60       | 0.1–3                  |                |
| C1   | M   | 64            | 10                       | L          | 1,290                 | 2.5             | 130       | 60       | 0.1–3                  |                |
| C2   | F   | 51            | 11                       | L          | 1,480                 | 3.5             | 130       | 60       | 0.1–3                  |                |
| C3   | M   | 61            | 15                       | L          | 875                   | 3               | 130       | 60       | 0.1–2.5                |                |
| C4   | M   | 70            | 19                       | L          | 1,280                 | 2.5             | 130       | 60       | 0.1–3                  |                |
| C5   | F   | 49            | 9                        | R          | 793                   | 1.5–2.5         | 130       | 60       | 0.14 ± 0.33 2.7 ± 0.67 |                |

### Notes
- **LEED**: levodopa equivalent daily dose; **UPDRS**: Unified Parkinson’s Disease Rating Scale.
- *Case B8 and C4 preoperative UPDRS III score data is missing.*
- Preoperative response to levodopa refers to UPDRS III score assessed by a neurologist at the time of indication for DBS surgery (≈6 months before surgery).
cDBS (N = 14, see Figure 1), using non-parametric statistics (Wilcoxon’s rank sum test, \( p < 0.05 \)).

Then, we investigated whether there was a correlation between aTEED and RDRS values, using Linear Regression Analysis conducted using the Spearman’s coefficient, since the cohort considered in this study is small (\( p < 0.05 \)). For the correlation analysis, we considered all data available for each patient (all evaluations in the Med On-Stim ON condition, both with aDBS and cDBS), for a total of \( N = 41 \) samples.

Throughout the text, all data are expressed as [mean ± standard error]. All analyses were carried out using the software MATLAB Version 9.3.0.713579 (R2017b, TheMathWorks Inc.,USA).

## RESULTS

Table 2 reports the means and standard error for aTEED and RDRS in each study protocol. No significant differences were observed neither in the normalized energy delivered (cDBS sessions \( p = 0.91 \), aDBS sessions \( p = 0.15 \)) nor in the normalized dyskinesia scores (cDBS sessions \( p = 0.07 \), aDBS sessions \( p = 0.08 \)), thus allowing to pool the data from these studies together.

As expected, we found that aTEED values were significantly lower in the aDBS than cDBS sessions (aTEED mean value, cDBS: 0.0278 ± 0.0011 j, vs. aDBS: 0.0071 ± 0.0003 j, \( p < 0.00001 \), Wilcoxon’s rank sum).

We also confirmed previous findings showing that aDBS is able to better control dyskinesias when the patients are in the ON medication state with DBS ON. The normalized RDRS assessed during both sessions was significantly lower during the aDBS than cDBS (normalized RDRS mean score, cDBS: 0.66 ± 0.017 vs. aDBS: 0.45 ± 0.01, \( p = 0.025 \), Wilcoxon’s rank sum test).

Finally, Figure 2 shows that there is a direct relationship between the amount of energy delivered by DBS and the amount of dyskinesias observed in each patient (\( \rho = 0.44, p = 0.0032 \), Spearman’s correlation).

## DISCUSSION

In this work, retrospectively evaluating the energy delivered to the tissue in LFP-based aDBS and cDBS, together with the amount of dyskinesia experienced by the patients in the ON medication-ON stimulation state, we provided, for the first time, a preliminary piece of evidence that stimulation-induced side effects are correlated with the electrical energy delivered to the tissue by DBS amplitude.

Even though aTEED reduction has been previously considered beneficial in several clinical trials on neurostimulation systems (33, 34) as a measure of safety, no direct evidence of a relationship between aTEED and the occurrence of adverse events was available in humans so far. Our results therefore support the possibility to use this parameter, which is an objective quantitative measure that can be provided directly by implanted devices, as a safety measure in future trials involving amplitude-controlled DBS.

In fact, in aDBS, it is possible to take advantage of the whole therapeutic window allowed by DBS (from the minimum effective amplitude to the maximum amplitude before the occurrence of stimulation-related side effects). This is not possible with cDBS because it is necessary to define a compromise between efficacy and long-term stimulation with fixed parameters (21). Therefore, aDBS can reach, for short time windows, amplitudes higher than cDBS, keeping the aTEED in any case lower than cDBS.

It is important to underline that a lower aTEED does not imply a lower battery consumption, at least in current aDBS technological implementations. In fact, the pulse generator has to include a sensing technology allowing biopotential recordings when DBS is turned ON (10) and this circuit consumes energy, possibly counterbalancing the benefits of lower stimulation. In addition, the use of aTEED has to consider a methodological limitation. The relation we found between energy delivered and neurophysiological/clinical effects cannot be considered monotonical or linear in general, but only in case of DBS with fixed pulse width and frequency. When more complex algorithms, involving the modulation of pulse width and/or frequency, will be implemented in aDBS systems, the linearity of the relationship would be lost and more complex mechanisms will be involved. Therefore, the role of TEED should be re-evaluated, and the use of aTEED would be not appropriate.

Even though evaluated retrospectively, these results seem to confirm, in a larger sample of patients, that LFP-based aDBS better controls levodopa-induced dyskinesias in the ON medication-ON stimulation state, as already reported (5, 6). Previous studies have recently shown a significant inverse correlation between subthalamic neuronal firing and total electrical energy delivered (TEED), with higher TEED leading to an increased suppression of neuronal firing (35). Given the

### TABLE 2 | Patient’s clinical assessments.

| Group | aTEED cDBS [mJ] | Normalized aTEED cDBS | aTEED aDBS [mJ] | Normalized aTEED aDBS | RDRS cDBS | Normalized RDRS cDBS | RDRS aDBS | Normalized RDRS aDBS |
|-------|----------------|-----------------------|----------------|-----------------------|-----------|----------------------|-----------|----------------------|
| A     | 22 ± 1.2       | 0.73 ± 0.042          | 6.4 ± 1.1      | 0.21 ± 0.038          | 5.7 ± 0.34| 0.71 ± 0.043          | 5.17 ± 0.41| 0.65 ± 0.062          |
| B*    | //             | //                    | 2.7 ± 0.2      | 0.22 ± 0.017          | //        | //                   | 6 ± 0.32   | 0.33 ± 0.018          |
| C     | 36.5 ± 2.9     | 0.70 ± 0.055          | 16.4 ± 1.1     | 0.31 ± 0.021          | 4 ± 0.27  | 0.5 ± 0.034          | 2.5 ± 0.18  | 0.31 ± 0.023          |
| Total Mean ± st.dev. | 28.6 ± 2.1 | 0.72 ± 0.047         | 10.95 ± 1.05   | 0.24 ± 0.033          | 4.9 ± 0.29| 0.61 ± 0.037         | 4.82 ± 0.41 | 0.43 ± 0.041          |

The three groups refer to A: (●); B: (●); C: in press.*B group protocol does not involve cDBS stimulation.

st.dev., standard deviation.
overall inhibitory role exerted by the subthalamus on the indirect basal ganglia pathway, we can hypothesize that lower aTEED leads to milder dyskinesias.

This work has however some limitations that should be taken into account when interpreting the results. First, in the study we pooled together the results of aDBS and cDBS in patients undergoing different protocols. The variability is mainly related to the total time of aDBS/cDBS delivery to the patients, being those coming from the first protocol studied for 2 h, while the others for 8 h. However, this variability is lowered by several aspects: the device (AlphaDBS-V-ext) is the same for all the studies; patients were all predominantly rigid-akinetic and were operated by the same surgical team, thus lowering the probability to introduce biases related to electrode positioning; the time frame considered to study the correlation between aTEED and dyskinesias is the same for all patients (20 min around the levodopa peak). Another limitation is that all studies were conducted in the acute setting, some days after the surgery for electrode placement, in a condition that is intrinsically biased by the microlesioning effect of lead placement, as well as by the possible presence of edema. In particular, regarding the aTEED calculation, the impedance in this specific time frame is lower than in the chronic setting (36), thus lowering the possibility to generalize our results. However, the impedance change over time should be consistent across subjects, thus limiting the effect on the correlation. Another point is that RDRS, while being an easy tool, focuses on functional ability, and does not consider the body spreading or duration of dyskinesia. Finally, we cannot rule out the possibility that the observed correlation is specific of the sample studied. This may be due to the fact that all patients received DBS implant in the same institution, thus limiting the effects of variable lead positioning due to heterogeneous procedures, and underwent the same type of aDBS. However, we are not proposing a regression model to establish a direct relationship between aTEED and dyskinesia scores, but we only verified the existence of a correlation. All these limitations can be mitigated designing a larger and prospective study, which should be able to confirm the hypothesis that the amount of energy delivered to the tissue in an amplitude-controlled approach is related to the occurrence of dyskinesias.

The present aDBS implementation, based on a single biomarker (beta band LFP) is limited by the fact that not all patients treated with DBS show a consistent beta peak (37), and, therefore, patients without significant beta activity were excluded from all the studies on closed-loop DBS (1, 5). This first biomarker was chosen because of its well-known and recognizable dynamic that made it as a suitable candidate for a first implementation. However, aDBS should be considered as a platform, in its very early stages, that will in the future provide personalized DBS therapy, with biomarkers specifically targeted on patient’s symptoms. The present preliminary results, together with the first implantable commercial devices (Medtronic Percept™, Newronika AlphaDBS System) with sensing capabilities currently under industry-sponsored clinical trials (i.e., NCT04547712 and NCT04681534), represent the starting point for such patient’s tailored DBS therapy.

In conclusion, our results provide a first piece of evidence that aTEED is correlated to the amount of levodopa-induced dyskinesias in patients with PD undergoing STN-DBS, with electrophysiological characteristics suitable for beta band LFP-based aDBS, thus supporting the role of this type of aDBS as feasible and safe alternative to cDBS.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethical Committee of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

SM and MP conceived the idea, participated to the experiments, conducted data analysis, drafted the manuscript and the figures,
and contributed to the design of the work and substantial revision of the work. TB, LB, and FC contributed in the design of the work and acquisition of data. PR and ML conducted the implantation surgery and contributed to data interpretation. All authors have approved the submitted version.

REFERENCES

1. Little S, Pogosyan A, Neal S, Zavala B, Zrinzo L, Hariz M, et al. Adaptive deep brain stimulation in advanced Parkinson disease. Ann Neurol. (2013) 74:449–57. doi: 10.1002/ana.23951
2. Little S, Beudel M, Zrinzo L, Foltynie T, Limousin P, Hariz M, et al. Bilateral adaptive deep brain stimulation is effective in Parkinson’s disease. J Neurol Neurosurg Psychiatry. (2016) 87:717–21. doi: 10.1136/jnnp-2015-310972
3. Little S, Tripoliti E, Beudel M, Pogosyan A, Cagnan H, Herz D, et al. Adaptive deep brain stimulation for Parkinson’s disease demonstrates reduced speech side effects compared to conventional stimulation in the acute setting. J Neurol Neurosurg Psychiatry. (2016) 2016:313518. doi: 10.1136/jnnp-2016-313518
4. Rosa M, Arlotti M, Ardolino G, Cogiamanian F, Marceglia S, Di Fonzo A, et al. Adaptive deep brain stimulation in a freely moving Parkinsonian patient. Mov Disord. (2015) 30:1003–5. doi: 10.1002/mds.26241
5. Rosa M, Arlotti M, Marceglia S, Cogiamanian F; Ardolino G, Fonzo A, et al. Adaptive deep brain stimulation controls levodopa-induced side effects in Parkinsonian patients. Mov Disord. (2017) 32:628–9. doi: 10.1002/mds.26953
6. Arlotti M, Marceglia S, Foffani G, Volkmann J, Lozano AM, Moro E, et al. Eight-hours adaptive deep brain stimulation in patients with Parkinson disease. Neurology. (2018) 90:e971–6. doi: 10.1212/WNL.0000000000005121
7. Arlotti M, Palmisano C, Minafra B, Todisco M, Pacchetti C, Canessa A, et al. Monitoring subthalamic oscillations for 24 hours in a freely moving Parkinson’s disease patient. Mov Disord. (2019) 34:757–9. doi: 10.1002/mds.27657
8. Swann NC, de Hemptinne C, Thompson MC, Micinovic S, Miller AM, Gilron R, et al. Adaptive deep brain stimulation for Parkinson’s disease using motor cortex sensing. J Neurol. (2018) 15:046006. doi: 10.1088/1741-2552/aabc9b
9. Priori A, Foffani G, Rossi L, Marceglia S. Adaptive deep brain stimulation (aDBS) controlled by local field potential oscillations. Exp Neurol. (2013) 245:77–86. doi: 10.1016/j.expneurol.2012.09.013
10. Arlotti M, Rosa M, Marceglia S, Barbieri S, Priori A. The adaptive deep brain stimulation challenge. Parkinsonism Relat Disord. (2016) 28:12–7. doi: 10.1016/j.parkreldis.2016.03.020
11. Price JB, Rusheen AE, Barath AS, Rojas Cabrera JM, Shin H, Chang S-Y, et al. Clinical applications of neurochemical and electrophysiological measurements for closed-loop neurostimulation. Neurotherapeutics. Focus. (2020) 49:6. doi: 10.3171/2020.4.FOCUS20167
12. Kraus JK, Lipman N, Aziz T, Boutet A, Brown P, Chang JW, et al. Technology of deep brain stimulation: current status and future directions. Nat Rev Neurosci. (2021) 17:75–87. doi: 10.1038/s41582-020-00426-z
13. Giannicola G, Rosa M, Marceglia S, Selzo E, Rossi L, Servello D, et al. The effects of levodopa and deep brain stimulation on subthalamic local field low-frequency oscillations in Parkinson’s disease. Neurosci Letts. (2005) 319:89–98. doi: 10.1011/003363543
14. Stanslaski S, Ashar P, Cong P, Gifftakis J, Strypulkowski P, Carlson D, et al. Design and validation of a fully implantable, chronic, closed-loop neuromodulation device with concurrent sensing and stimulation. IEEE Trans Neural Syst Rehabil Eng. (2012) 20:410–21. doi: 10.1109/TNSRE.2012.2183617
15. Moreau C, Defebvre L, Destee A, Bleuse S, Clement F, Blatt JL, et al. STN-DBS frequency effects on freezing of gait in advanced Parkinson disease. Neurology. (2008) 71:80–4. doi: 10.1212/01.wnl.0000303972.16279.46
16. Xie T, Padmanaban M, Bloom L, MacCracken E, Bertacchi B, Dachman A, et al. Effect of low versus high frequency stimulation on freezing of gait and other axial symptoms in Parkinson patients with bilateral STN DBS: a mini-review. Transl Neurodegener. (2017) 6:13. doi: 10.1186/s40335-017-0083-7
17. Reich MM, Steigerwald F, Sawalhe AD, Reese R, Gunalan K, Johannes S, et al. Short pulse width widens the therapeutic window of subthalamic neurostimulation. Ann Clin Transl Neurol. (2015) 2:427–32. doi: 10.1002/acn3.168
18. Kroneberg D, Ewert S, Meyer A-C, Kuhn AA. Shorter pulse width reduces gait disturbances following deep brain stimulation for essential tremor. J Neurol Neurosurg Psychiatry. (2019) 90:1046–50. doi: 10.1136/jnnp-2018-3 19427
19. Beudel M, Brown P. Adaptive deep brain stimulation in Parkinson’s disease. Parkinsonism Related Disc. (2016) 22:5123–6. doi: 10.1016/j.parkreldis.2015.09.028
20. Piña-Fuentes D, Beudel M, Little S, Brown P, Oterdoom DLM, van Dijk JMC. Adaptive deep brain stimulation as advanced Parkinson’s disease treatment (ADAPT study): protocol for a pseudo-randomised clinical study. BMJ Open. (2019) 9:e026562. doi: 10.1136/bmjopen-2019-0 29652
21. Moro E, Poon Y-YW, Lozano AM, Saint-Cyr JA, Lang AE. Subthalamic nucleus stimulation: improvements in outcome with reprogramming. Arch Neurol. (2006) 63:1266–72. doi: 10.1001/archneur.2006.9.1266
22. Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Vollmann J, Stefani A, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. (2011) 68:165. doi: 10.1001/archneur.2010.260
23. Buhmann C, Huckhagel T, Engel K, G ultberti A, Hidding U, Poetter-Nerger M, et al. Adverse events in deep brain stimulation: a retrospective long-term analysis of neurological, psychiatric and other occurrences. Plone. (2017) 12:e0179894. doi: 10.1371/journal.pone.0179894
24. Krak P, Martinez-Fernandez R, del Alamo M, Obeso JA. Current applications and limitations of surgical treatments for movement disorders: surgical treatments for movement disorders. Movement Disord. (2017) 32:36–52. doi: 10.1002/mds.26890
25. Fasano A, Aquino CC, Krauss JK, Honey CR, Bloem BR. Axial disability and deep brain stimulation in patients with Parkinson disease. Nat Rev Neurol. (2015) 11:98–110. doi: 10.1038/nrneurol.2014.252
26. Dowsey-Limousin P. Postoperative management of Vim DBS for tremor. Mov Disord. (2002) 17:5208–11. doi: 10.1002/mds.10165
27. Abbes M, Lhomée E, Thobois S, Klinger H, Schmitt E, Bichon P, et al. Short pulse width widens the therapeutic window of subthalamic neurostimulation for Parkinson’s disease. Mov Disord. (2015) 11:98–110. doi: 10.1002/mds.26890
28. Chen CC, Brucke C, Kempf F, Kupsch A, Lu CS, Lee ST, et al. Deep brain stimulation of the subthalamic nucleus: results from a long-term follow-up cohort study. J Neurosurg. (2018) 89:363–43. doi: 10.1016/j.jns.2017-3 16373
29. Ray NJ, Jenkinson N, Brittain J, Holland P, Joint C, Nandi D, et al. The role of the subthalamic nucleus in response inhibition: evidence from deep brain stimulation for Parkinson’s disease. Neuropsychologia. (2009) 47:2828–34. doi: 10.1016/j.neuropsychologia.2009.06.011
30. Koss AM, Alterman RL, Tagliati M, Shils JI. Calculating total electrical energy delivered by deep brain stimulation systems. Ann Neurol. (2005) 58:168–168. doi: 10.1002/ana.20525
31. Arlotti M, Rossi L, Rosa M, Marceglia S, Priori A. An external portable device for adaptive deep brain stimulation (aDBS) clinical research in advanced Parkinson’s disease. Mov Disord. (2002) 17:5188–97. doi: 10.1002/mds.10163

FUNDING

This research was partially supported by the grant Roche for Research 2017 for Neuroscience and by a donation in memory of Aldo Ravelli.
33. Harries AM, Major S, Sandhu M, Honey CR. Rechargeable internal neural stimulators—is there a problem with efficacy?: Rechargeable Internal Neural Stimulators. Neuromodulation. (2012) 15:214–8. doi: 10.1111/j.1525-1403.2011.00406.x

34. Tsang EW, Hamani C, Moro E, Mazzella F, Saha U, Lozano AM, et al. Subthalamic deep brain stimulation at individualized frequencies for Parkinson disease. Neurology. (2012) 78:1930–8. doi: 10.1212/WNL.0b013e318259e183

35. Milosevic I, Kalia SK, Hodaie M, Lozano A, Popovic MR, Hutchison W. Subthalamic suppression defines therapeutic threshold of deep brain stimulation in Parkinson’s disease. J Neurol Neurosurg Psychiatr. (2019) 90:1105–8. doi: 10.1136/jnnp-2019-321440

36. Rosa M, Giannicola G, Servello D, Marceglia S, Pacchetti C, Porta M, et al. Subthalamic local field beta oscillations during ongoing deep brain stimulation in Parkinson’s disease in hyperacute and chronic phases. Neurosignals. (2011) 19:151–62. doi: 10.1159/000328508

37. Giannicola G, Marceglia S, Rossi L, Mrakic-Sposta S, Rampini P, Tamma F, et al. The effects of levodopa and ongoing deep brain stimulation on subthalamic beta oscillations in Parkinson’s disease. Exp Neurol. (2010) 226:120–7. doi: 10.1016/j.expneurol.2010.08.011

Conflict of Interest: SM, AP, SB, FC, PR, and ML are founder and shareholder of Neuronika SpA, a spin-off company of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico and of the University of Milan. MA was employed by the company Neuronika SpA.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Prenassi, Arlotti, Borellini, Bocci, Cogiamanian, Locatelli, Rampini, Barbieri, Priori, and Marceglia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.